Last updated: 2026-10-12 21:32:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Cingulate Inc. (CING) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.84, with a market capitalisation of $71.11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.16 to $11.89. This page covers its latest market performance, valuation, price trends and company information.
$71.11M | |
$4.81 | |
$1,236.00 | |
$1.80 | |
$4.89 | |
28.94K | |
130.35K | |
-- | |
$11.89 | |
$3.16 | |
-- | |
-- |
Cingulate Inc. (CING) is trading at $4.84 in after-hours trading as of 2026-10-12 20:11:00, down 1.12% ($0.05) from the regular-session close of $4.89.
After-hours trading shows how investors are pricing CING after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Cingulate Inc. (CING) moved from $4.75 to $4.84, representing a gain of 1.92% ($0.09).
The stock traded between $4.63 and $5.00 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 81.78 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 19.3%
CING is currently trading at $4.84, placing it 19.3% of the way from its 52-week low of $3.16 to its 52-week high of $11.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cingulate Inc. (CING) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.